Oregon Health Authority mandates newborn screening for cytomegalovirus within 14 days

The Oregon State Legislature has introduced House Bill 2685, aimed at enhancing the early detection and management of congenital cytomegalovirus (CMV) in newborns. Introduced on April 7, 2025, the bill seeks to establish a comprehensive screening protocol for CMV, which is a leading cause of hearing loss and developmental disabilities in children.

The key provisions of House Bill 2685 include mandatory screening for CMV within 14 days of birth at hospitals and birthing centers, unless parents object in writing. The bill also mandates that health benefit plans cover the costs associated with CMV testing. Additionally, the Oregon Health Authority is tasked with developing an expanded screening protocol based on evidence-based practices, as well as compiling and disseminating educational materials regarding CMV to healthcare providers and the public.

Debate surrounding the bill has focused on the implications of mandatory testing and the potential burden on healthcare facilities. Some lawmakers express concerns about the costs associated with implementing the new screening protocol, while advocates argue that early detection can lead to better health outcomes for affected infants. Amendments to the bill have been proposed to address these concerns, including provisions for exemptions based on parental objections.

The significance of House Bill 2685 lies in its potential to improve early diagnosis and treatment of CMV, which could significantly reduce the long-term health impacts on affected children. Experts in pediatric health have emphasized the importance of early intervention, suggesting that the bill could lead to better developmental outcomes and reduced healthcare costs in the long run.

As the bill progresses through the legislative process, its future remains uncertain, with ongoing discussions about its financial implications and the balance between public health initiatives and parental rights. If passed, House Bill 2685 could mark a significant step forward in addressing congenital CMV in Oregon, setting a precedent for similar initiatives in other states.